Impax Laboratories Management Discusses Q2 2012 Results - Earnings Call Transcript
Impax Laboratories (IPXL)
Q2 2012 Earnings Call
July 31, 2012 11:00 am ET
Executives
Mark Donohue - Senior Director of Investor Relations & Corporate CommunicationsLarry Hsu - Chief Executive Officer, President and DirectorBryan M. Reasons - Acting Chief Financial OfficerMichael J. Nestor - Divisional President of Impax PharmaceuticalsCarole S. Ben-Maimon - President of Global Pharmaceuticals DivisionAnalystsShibani Malhotra - RBC Capital Markets, LLC, Research DivisionCorey B. Davis - Jefferies & Company, Inc., Research DivisionRandall Stanicky - Canaccord Genuity, Research DivisionElliot Wilbur - Needham & Company, LLC, Research DivisionGregory Waterman - Goldman Sachs Group Inc., Research DivisionSumant S. Kulkarni - BofA Merrill Lynch, Research DivisionDavid Amsellem - Piper Jaffray Companies, Research DivisionMichael Kallai Tong - Wells Fargo Securities, LLC, Research DivisionDewey SteadmanKen Cacciatore - Cowen and Company, LLC, Research DivisionAmi Fadia - UBS Investment Bank, Research DivisionJames F. Molloy - ThinkEquity LLC, Research DivisionPresentationOperatorPrevious Statements by IPXL
» Impax Laboratories Management Discusses Q3 2010 Results – Earnings Call Transcript
» Impax Laboratories Inc. Q2 2010 Earnings Call Transcript
» Impax Laboratories Inc. Q1 2010 Earnings Call Transcript
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
TheStreet Quant Ratings
TRY IT FREENew! $49.95/yr
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Product Features:
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Dividend Stock Advisor
TRY IT FREEJim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
